Trial Profile

Clinical Study of Chimeric CD(Cluster of Differentiation)19 Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory B-cell Leukemias and Lymphomas

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti CD19 chimeric antigen receptor T cell therapy AbelZeta Pharma (Primary)
Indications B-cell prolymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Leukaemia
Focus Adverse reactions
Acronyms CART19

Most Recent Events

25 Mar 2015 Status changed from recruiting to active, no longer recruiting, based on a Cellular Biomedicine Group media release.
25 Mar 2015 Results published in a Cellular Biomedicine Group media release.
27 Feb 2015 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com